Peptides DB
Research-centric peptide and protocol reference hub
Study 6 of 6Pemvidutide literatureDigestive diseases (Basel, Switzerland) · Meta-analysis2026

GLP-1/Glucagon Receptor Dual Agonists for Metabolic Dysfunction-Associated Steatohepatitis and Steatotic Liver Disease (MASH/MASLD): A Systematic Review and Meta-Analysis.

GLP-1/glucagon dual receptor agonists showed a higher likelihood of MASH resolution and significant reductions in liver fat, but gastrointestinal side effects were more common.

Read at Digestive diseases (Basel, Switzerland)Add to compare

Where it sits

this study against the rest of the pemvidutide corpus
0
Preclinical
1
Observational
1
Open-label
1
Randomised
3
Reviews · this one

Summary and findings

This systematic review and meta-analysis evaluated the effects of GLP-1/glucagon dual receptor agonists on metabolic dysfunction-associated steatohepatitis (MASH) in adults. Four trials involving a total of 673 participants were analyzed. The results indicated an increase in MASH resolution and reductions in liver fat and liver enzymes, but also noted an increase in gastrointestinal adverse events.

How much of this paper we could read: full text read (0.80). We had a clear abstract, so the summary below closely tracks the paper. What this means →
RR 2.98 for MASH resolution without worsening of fibrosis, 95% CI 2.09-4.24, k=2.2026

Abstract

The authors’ words, as Digestive diseases (Basel, Switzerland) supplied them

<h4>Background</h4>Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive liver disease with high unmet therapeutic need. GLP-1/glucagon dual receptor agonists are an emerging drug class, but no meta-analysis has evaluated it exclusively.<h4>Methods</h4>In this registered systematic review and meta-analysis (PROSPERO CRD420261325731), we searched PubMed, Embase, Cochrane, and Google Scholar through January 2026 for placebo-controlled randomized trials of GLP-1/glucagon dual agonists in adults with MASH or MASLD. Four trials (survodutide, pemvidutide, cotadutide; n=673) were pooled with DerSimonian-Laird random-effects models; Hartung-Knapp-Sidik-Jonkman adjustment was a sensitivity analysis.<h4>Results</h4>Dual agonists increased MASH resolution without worsening of fibrosis (RR 2.98, 95% CI 2.09-4.24; k=2). A borderline, exploratory signal for fibrosis improvement was observed (RR 1.38, 95% CI 1.01-1.88; p=0.044; k=2); neither trial was individually significant. Relative liver fat fell by 46.24% (95% CI -55.24 to -37.24), and ≥30% liver fat reduction was more frequent (RR 4.39, 95% CI 2.97-6.49). ALT (MD -20.38 IU/L, 95% CI -33.00 to -7.75), AST (MD -18.80 IU/L), body weight (MD -4.36%) and systolic blood pressure (MD -5.22 mmHg) decreased; the ELF reduction was not retained in sensitivity analyses. Nausea (RR 2.90), vomiting (RR 9.58) and diarrhea (RR 1.90) were more frequent; serious adverse events were not (RR 1.06). Split-placebo analyses were consistent.<h4>Conclusions</h4>Dual agonists were associated with a higher likelihood of MASH resolution, a borderline exploratory fibrosis signal, and reductions in liver fat, liver enzymes, weight and systolic blood pressure, with more gastrointestinal adverse events. These early-phase findings support continued Phase 3 evaluation.

Background

Not reported in abstract.

Methods

Not reported in abstract.

Results

Not reported in abstract.

Interpretation

Not reported in abstract.

Limitations

Not reported in abstract.

Elsewhere in the Pemvidutide corpus

ASafety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study.Lancet (London, England) · 2025 · MASH resolution without fibrosis worsening: 58% in 1.2 mg pemvidutide group, p<0.0001.HumanAThe dual GLP-1-glucagon agonist pemvidutide in MASH: a phase 2b trial.Lancet (London, England) · 2025HumanDGlucagon-like peptide 1 receptor agonists in substance use disorders: A systematic review of ClinicalTrials.Gov.Addictive behaviors reports · 2026 · Not reported in abstract.reviewDEfficacy and safety of pemvidutide in metabolic dysfunction-associated steatohepatitis: a GRADE-assessed meta-analysis of randomized controlled trials.Naunyn-Schmiedeberg's archives of pharmacology · 2026 · -52.90 MD liver fat content at 12 weeks, 95% CI -71.60 to -34.20, P < 0.00001reviewDEfficacy and Safety of Dual and Triple Glucagon-Like Peptide-1-Based Polyagonists in Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis: A Systematic Review and Meta-Analysis.Cureus · 2026 · RR 3.32, 95% CI 2.28-4.84; I² = 20% for MASH resolution or histological improvement without worsening of fibrosis.review